pplication of MicroRNAs in Diagnosis and Treatment of Oral Leukoplakia

doi:10.13701/j.cnki.kqyxyj.2022.09.002

Abstract

Abstract: MicroRNA (miRNA) is an endogenous highly conserved non-coding RNA, which is involved in various biological activities of the body, and is closely related to the development of a variety of cancers. Recent studies have shown the potential of miRNAs as a molecular marker for malignant transformation of oral leukoplakia and therapeutic target of oral leukoplakia. In this study, the application of miRNAs in the diagnosis and treatment of oral leukoplakia was reviewed.

Key words: microRNA, oral leukoplakia, malignant transformation

LIU Jiaxin, DAN Hongxia. pplication of MicroRNAs in Diagnosis and Treatment of Oral Leukoplakia[J]. Journal of Oral Science Research, 2022, 38(9): 807-810.

References

[1] Mello FW, Miguel AFP, Dutra KL, et al. Prevalence of oral potentially malignant disorders: A systematic review and meta-analysis [J]. J Oral Pathol Med, 2018, 47(7):633-640.
[2] Pinto AC, Caramês J, Francisco H, et al. Malignant transformation rate of oral leukoplakia-systematic review [J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2020, 129(6):600-611.
[3] 杨凯成,杨蕾,赵建广,等. 口腔鳞状细胞癌患者外周血microRNA的表达及预后意义[J]. 口腔医学研究,2020, 36(5):428-432.
[4] Ghafouri-Fard S, Shoorei H, Anamag FT, et al. The role of non-coding RNAs in controlling cell cycle related proteins in cancer cells [J]. Front Oncol, 2020, 10:608975.
[5] Niu T, Zhang W, Xiao W. MicroRNA regulation of cancer stem cells in the pathogenesis of breast cancer [J]. Cancer Cell Int, 2021, 21(1):31.
[6] Torsin LI, Petrescu GED, Sabo AA, et al. Editing and chemical modifications on non-coding RNAs in cancer: A new tale with clinical significance [J]. Int J Mol Sci, 2021, 22(2):581.
[7] Volovat SR, Volovat C, Hordila I, et al. MiRNA and lncRNA as potential biomarkers in triple-negative breast cancer: A review [J]. Front Oncol, 2020, 10:526850.
[8] Iqbal MA, Arora S, Prakasam G, et al. MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance [J]. Mol Aspects Med, 2019, 70:3-20.
[9] Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs [J]. Cell, 2009, 136(4):642-655.
[10] Ruby JG, Jan CH, Bartel DP. Intronic microRNA precursors that bypass Drosha processing [J]. Nature, 2007, 448(7149):83-86.
[11] Chen D, Cabay RJ, Jin Y, et al. MicroRNA deregulations in head and neck squamous cell carcinomas [J]. J Oral Maxillofac Res, 2013, 4(1):e2.
[12] Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, et al. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods [J]. J Cell Physiol, 2019, 234(5):5451-5465.
[13] Bayraktar R, Van Roosbroeck K, Calin GA. Cell-to-cell communication: microRNAs as hormones [J]. Mol Oncol, 2017, 11(12):1673-1686.
[14] Ouyang T, Liu Z, Han Z, et al. MicroRNA detection specificity: Recent advances and future perspective [J]. Anal Chem, 2019, 91(5):3179-3186.
[15] Cheng Y, Dong L, Zhang J, et al. Recent advances in microRNA detection [J]. Analyst, 2018, 143(8):1758-1774.
[16] Tian T, Wang J, Zhou X. A review: microRNA detection methods [J]. Org Biomol Chem, 2015, 13(8):2226-2238.
[17] Villa A, Sonis S. Oral leukoplakia remains a challenging condition [J]. Oral Dis, 2018, 24(1-2):179-183.
[18] Monteiro L, Mello FW, Warnakulasuriya S. Tissue biomarkers for predicting the risk of oral cancer in patients diagnosed with oral leukoplakia: A systematic review[J]. Oral Dis, 2021, 27(8):1977-1992.
[19] Liu CJ, Tsai MM, Hung PS, et al. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma[J]. Cancer Res, 2010, 70(4):1635-1644.
[20] Liu CJ, Lin SC, Yang CC, et al. Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma [J]. Head Neck, 2012, 34(2): 219-224.
[21] Liu C, Kao S, Tu H, et al. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer [J]. Oral Dis, 2010, 16(4):360-364.
[22] Chang KW, Kao SY, Wu YH, et al. Passenger strand miRNA miR-31^* regulates the phenotypes of oral cancer cells by targeting RhoA [J]. Oral Oncol, 2013, 49(1):27-33.
[23] Xiao W, Bao ZX, Zhang CY, et al. Upregulation of miR-31^* is negatively associated with recurrent/newly formed oral leukoplakia [J]. PLoS One, 2012, 7(6):e38648.
[24] Maimaiti A, Abudoukeremu K, Tie L, et al. MicroRNA expression profiling and functional annotation analysis of their targets associated with the malignant transformation of oral leukoplakia [J]. Gene, 2015, 558(2):271-277.
[25] Roy R, Singh R, Chattopadhyay E, et al. MicroRNA and target gene expression based clustering of oral cancer, precancer and normal tissues [J]. Gene, 2016,593(1):58-63.
[26] Chen H, Liu X, Jin Z, et al. A three miRNAs signature for predicting the transformation of oral leukoplakia to oral squamous cell carcinoma [J]. Am J Cancer Res, 2018, 8(8):1403-1413.
[27] Philipone E, Yoon AJ, Wang S, et al. MicroRNAs-208b-3p, 204-5p, 129-2-3p and 3065-5p as predictive markers of oral leukoplakia that progress to cancer [J]. Am J Cancer Res, 2016, 6(7):1537-1546.
[28] Cervigne NK, Reis PP, Machado J, et al. Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma [J]. Hum Mol Genet, 2009, 18(24):4818-4829.
[29] Brito JAR, Gomes CC, Guimares ALS, et al. Relationship between microRNA expression levels and histopathological features of dysplasia in oral leukoplakia [J]. J Oral Pathol Med, 2014, 43(3):211-216.
[30] Ranganathan K, Kavitha L. Oral epithelial dysplasia: Classifications and clinical relevance in risk assessment of oral potentially malignant disorders [J]. J Oral Maxillofac Pathol, 2019, 23(1):19-27.
[31] Holmstrup P, Vedtofte P, Reibel J, et al. Oral premalignant lesions: is a biopsy reliable? [J]. J Oral Pathol Med, 2007, 36(5):262-266.
[32] Li W, Han Y, Zhao Z, et al. Oral mucosal mesenchymal stem cellderived exosomes: A potential therapeutic target in oral premalignant lesions [J]. Int J Oncol, 2019, 54(5):1567-1578.
[33] Wang L, Yin P, Wang J, et al. Delivery of mesenchymal stem cells-derived extracellular vesicles with enriched miR-185 inhibits progression of OPMD [J]. Artif Cells Nanomed Biotechnol, 2019, 47(1):2481-2491.